PAP
WVE icon

Persistent Asset Partners’s Wave Life Sciences WVE Stock Holding History

Persistent Asset Partners’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,827
Closed -$337K – 486
2025
Q4 		$337K Buy
+19,827
New +$201K 0.15% 171

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $602M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Persistent Asset Partners's WVE Position: Q1 2026 in Review

Persistent Asset Partners sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 19,827 shares — an estimated $337K sold.

Persistent Asset Partners first reported a position in WVE in Q4 2025 and held it in 1 quarter. The position peaked at $337K in Q4 2025. 232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Persistent Asset Partners reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 19,827 Wave Life Sciences shares in Q1 2026, an estimated $337K.
  • Persistent Asset Partners first reported a position in Wave Life Sciences in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Wave Life Sciences position peaked at $337K in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.